Adtec at the Diabetic Foot Study Group conference in Bratislava
Don't forget to visit us at the Diabetic Foot Study Group (DFSG) conference this weekend. We're having a great time welcoming you to our booth. Our SteriPlas is here ready to give you a live demonstration on how easy it is to use.
TSBIWH Annual Meeting & Symposium in Taiwan
An eventful weekend for our distributor in Taiwan as they demonstrate the strong antibacterial efficacy of the Adtec SteriPlas to health care professionals at the TSBIWH 2022 Annual Meeting and Symposium.
Presentation at the DFSG 2022
We're so excited for exhibiting at the Diabetic Foot Study Group (DFSG) conference next week. Please be sure to visit us at booth no.11 where we will based during the conference. We welcome you to see our SteriPlas Cold Plasma medical device live in action.
We're also excited to announce that the Diabetes Team at Kettering General Hospital NHS Foundation Trust will have a poster presentation illustrating the strong antibacterial efficacy and healing qualities of the Adtec SteriPlas for diabetic foot ulcers.
The poster, "DGH EXPERIENCE OF USING COLD PLASMA MEDICAL DEVICE AS AN ADJUNCT THERAPY TO ANTIMICROBIALS IN TREATING CHRONIC NON HEALING INFECTED DIABETIC FOOT ULCERS" will be presented by Jemma Cruickshank on Saturday 17th September, 13:25 - 14:25.
See you all soon!
The ISHLT discusses the Cold Plasma Project
We’re ecstatic to see our Adtec SteriPlas continue to raise awareness in the LVAD community. A great interview between the ISHLT and Mr Thomas Schlöglhofer from the Medical University of Vienna discussing the benefits of our cold atmospheric plasma medical device for the treatment of LVAD Infections and their broad study being conducted.
Thomas has been an avid user of our medical device for some time now collecting remarkable results with his LVAD patients, documenting the strong benefits of our medical device including the significant reduction of infection rates coupled with full healing, reduction of readmittance and the stabilisation of LVAD systems all with the added benefit of no side effects.
We look forward to the completion of this study and the publishing of the data which will be discussed at the ISHLT 2023 conference next year. We will also be exhibiting at this conference and excited to meet more people from the LVAD community.
https://youtu.be/6-L0sgXLx9o
Antimicrobial (antibiotic) Resistance – the drugs won’t work !
Antimicrobial resistance (AMR) poses a significant global threat of far-reaching proportions. It is estimated that drug resistant infections contribute to nearly 5 million deaths every year and predicted to increase to over 10 million deaths every year. WHO has declared that AMR is one of the top 10 global public health threats facing humanity.
(The worldwide total deaths from COVID is now just over 6 million and we all know how frightening it was before the vaccine was developed)
AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result, the medicines become ineffective and infections persist in the body, increasing the risk of spread to others. Microorganisms that develop antimicrobial resistance are sometimes referred to as “superbugs”. Without effective antimicrobials, the success of modern medicine in treating infections, including during major surgery and cancer chemotherapy, would be at increased risk. Chronic infections if left untreated could result in tissue damage, amputation, longer stays in hospitals, surgical interventions, or increased possibility of mortality. Patients who are infected with drug-resistant infections are more likely to develop complications and are up to three times more likely to die from the infection. Non-healing wounds in particular, are characterised by complex and mixed bacterial populations, often involving antibiotic-resistant bacteria as well as phenotypically tolerant bacteria in biofilm form. The biofilm factor is clearly of considerable clinical importance: it protects bacteria from antimicrobial agents leading to persistent and difficult to treat chronic infections, and it exacerbates the spread of antibiotic resistance. Surgical Site Infections are also linked to anti-microbial resistance.
SteriPlas cold plasma technology kills bacteria by a physical mode of action and bacteria are therefore unlikely to develop primary or secondary resistance, which we have documented from our clinical studies. SteriPlas cold plasma also kills antibiotic resistant bacteria (e.g. MRSA) and kills bacteria encased in biofilm which are typically up to 1000 times more resistant to antibiotics. SteriPlas has proven clinical efficacy in treating wound infections, diabetic foot infections and surgical site infections in all clinical studies, all with the bonus of no side effects reported.
SteriPlas cold plasma can be used to treat topical infections reserving antibiotics for severe systemic infections.
References
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext
https://www.worldometers.info/coronavirus/
https://www.who.int/health-topics/antimicrobial-resistance
https://healthfirsteurope.eu/wp-content/uploads/2020/11/A3A4-48pp-Booklet-Spreads-1.pdf
Bowler, P., Murphy, C. & Wolcott, R. Biofilm exacerbates antibiotic resistance: Is this a current oversight in antimicrobial stewardship?. Antimicrob Resist Infect Control 9, 162 (2020).
Diabetic Foot Study Group Conference
Are you excited as we are?
Looking forward to resuming exhibition season at the Diabetic Foot Study Group conference in Slovakia.
We'll be exhibiting between 16-18 Sept with our Adtec SteriPlas on demonstration ready to show you just how quick and effective it is to use and combat antibiotic resistant bacteria within diabetic foot ulcers.
Welcoming delegates at The Malvern Diabetic Foot conference
We’re having a great time welcoming you all to our booth at the Malvern Diabetic Foot Conference, introducing you all to the benefits of the SteriPlas cold plasma for the treatment of diabetic foot ulcers.
For those wishing to learn more about our clinical efficacy in diabetic foot ulcers, please contact us at info@adtecplasma.com for more information.
Welcoming Cardiothoracic Specialists at The SCTS
We're having a great time at the Society for Cardiothoracic Surgery in GB & Ireland conference, introducing the strong benefits of our Adtec SteriPlas cold plasma for deep sternal wound infections.
Please do pop by & see us at booth 18 to see our medical device in action.
The ISHLT Award Goes to Thomas Schlöglhofer!
Congratulations to Thomas Schlöglhofer and his team at the Medical University Hospital in Vienna for winning the ISHLT (International Society for Heart and Lung Transplantation) grant award, sponsored by Abbott and Medtronic.
This prestigious award given to Thomas is for his fantastic work using our Adtec SteriPlas medical device for the successful healing of LVAD Infections.
We look forward to continuing to support Thomas and his team and their presentation of the study at the ISHLT 2023 conference next year.
Next week welcomes the start of the exhibition season
Find us next week at the Society for Cardiothoracic Surgeons in Belfast from 8-10 May. We'll be at booth 18 ready to welcome you and introduce the benefits of #coldplasma in cardiothoracic #infection conditions.
From 10-13 May, we will also be exhibiting at the Malvern Diabetic Foot Conference looking forward to seeing regular faces from this prestigious conference.
We will have our Adtec SteriPlas medical device on our booths, ready to give you a live demonstration of how effective cold plasma is at killing bacteria protected within biofilm.
